Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

aseline International Prostate Symptom Score (IPSS) and uroflow values. Afterwards, 144 patients meeting the inclusion criteria were randomly allocated to one of five treatment groups with the following dosage regimens:

    - Placebo;

    - Ozarelix 5 mg on Day 1 + 5 mg on Day 15;

    - Ozarelix 10 mg on Day 1 +10 mg on Day 15;

    - Ozarelix 15 mg on Day 1 + 15 mg on Day 15; or

    - Ozarelix 20 mg on Day 1 only.

Patients were followed for 28 weeks. The primary efficacy endpoint was change in IPSS at week 12 compared to baseline. Secondary efficacy endpoints included changes in IPSS, Quality of Life (QoL), patients with >= 30% and >= 40% improvement in IPSS, uroflow values (Qmax), postvoid residual (PVR) urine volume and prostate volume. Safety analysis included changes in sexual function (IIEF-5), treatment of emergent adverse events (AEs), lab values (including testosterone (T), PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec. and prostate size (cm(3)) 41.6 at baseline.

Results

The effects developed rapidly, with noticeable activity at four weeks from starting treatment, were maximal at 12-16 weeks, and persisted for the 6 month observation period. At week 12, all ozarelix-treated groups showed improvement with the greatest improvement in the 15 mg + 15 mg group. Change from baseline in IPSS was 8.6 (p<0.001); change from baseline in urine flow was 4.7 (p=0.002); T levels declined transiently and returned to baseline in most patients by 4 weeks and all patients by 6 weeks following dosing. Based on IIEF, there was no effect seen on erectile function.

Serious adverse events were reported in 4 patients on ozarelix (myocardial infarction, pneumonitis, hypotension, renal colic), but were not considered treatment related. No systemic allergic reactions were seen and the injections were well tolerated.

    Conclusions


    - Ozarelix was well tolerated;

    - Statistically sig
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... COSTA MESA, Calif., Feb. 10, 2011 Renaissance Surgical Arts ... outpatient surgery center in the Western United States to offer ... device used in the TARGIT-A multicenter human clinical trial that ... certain women with early breast cancer. IORT ...
... Feb. 10, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... Vice President, Finance and Chief Financial Officer. Mr. Hoffman, who has ... his current role at Arena until the reporting of the company,s ... year ended December 31, 2010. "We thank Robert for ...
Cached Medicine Technology:Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 2Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 3
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
(Date:1/22/2015)... January 22, 2015 State Forestry Institute ... management system with support from GEOSYSTEMS, a dedicated Hexagon ... solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... as well as point clouds and documents. This effort ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... AMSTERDAM and SAN DIEGO, July 15 Royal Philips (AEX: ... reached an agreement to acquire the assets of InnerCool Therapies Inc., ... management of a patient,s body temperature. InnerCool, a wholly-owned subsidiary of ... acquired in an asset purchase transaction for US $11.25M, as well ...
... Discovery could pave the way for future targeted treatment, ... of circulating blood cells appear to be important predictors ... researchers. , They measured levels of circulating endothelial cells ... cancer, 22 children with metastatic cancer and 20 healthy ...
... , , , NORTH ... hot flashes, night sweats and mood swings, but a recent ... severity can have an overwhelmingly negative impact on every aspect ... by Duramed Pharmaceuticals, Inc., (now Teva Women,s Health, Inc.) a ...
... today the recipients of the 2009 World Federation of ... hemophilia education and training to nurses in developing countries ... supply. Three recipients were selected out of a pool ... , "Worldwide, about 70 percent of people with hemophilia ...
... , , SAN ... CADX ) announced today that its New Drug Application (NDA) for ... acute pain and fever in adults and children, has been accepted ... designated for Priority Review. Priority Review is granted to those products ...
... ... Daily Shot. It provides a "daily dose of sanity" for women dealing with ... , ... York, NY (PRWEB) July 15, 2009 -- FertilityAuthority introduces "The Daily Shot," an e-newsletter ...
Cached Medicine News:Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 2Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 3Health News:Rare Cells Linked to Pediatric Cancers 2Health News:Menopause Is More Than A Hot Flash 2Health News:Menopause Is More Than A Hot Flash 3Health News:Menopause Is More Than A Hot Flash 4Health News:Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 2Health News:Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 3Health News:Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 4Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 2Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 3Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 4Health News:FertilityAuthority Introduces E-Newsletter, The Daily Shot 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: